China's National Medical Products Administration approved Meheco's (SHA:600056) supplementary application for its vitamin B6 injection, according to a Wednesday filing with the Shanghai bourse.
The vitamin B6 injection could be used as a supplement for pregnant women and can treat radiation sickness, vomiting following chemotherapy, seborrheic dermatitis, and isoniazid or tuberculosis drug poisoning, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments